BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bradford PA, Miller AA, O'Donnell J, Mueller JP. Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates. ACS Infect Dis 2020;6:1332-45. [PMID: 32329999 DOI: 10.1021/acsinfecdis.0c00021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med 2022;14:eabo7793. [PMID: 35947678 DOI: 10.1126/scitranslmed.abo7793] [Reference Citation Analysis]
2 Hou Y, Mi K, Sun L, Zhou K, Wang L, Zhang L, Liu Z, Huang L. The Application of Hollow Fiber Cartridge in Biomedicine. Pharmaceutics 2022;14:1485. [DOI: 10.3390/pharmaceutics14071485] [Reference Citation Analysis]
3 Singh V, Mambwe D, Korkor CM, Chibale K. Innovation Experiences from Africa-Led Drug Discovery at the Holistic Drug Discovery and Development (H3D) Centre. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00142] [Reference Citation Analysis]
4 Kokot M, Anderluh M, Hrast M, Minovski N. The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV. J Med Chem 2022. [PMID: 35503563 DOI: 10.1021/acs.jmedchem.2c00039] [Reference Citation Analysis]
5 Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D, Engelhart C, Meshanni J, Byl JAW, Osheroff N, Singh V, Chibale K, Basarab GS. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. J Med Chem 2022. [PMID: 35500229 DOI: 10.1021/acs.jmedchem.2c00266] [Reference Citation Analysis]
6 Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. Front Pharmacol 2022;13:874176. [DOI: 10.3389/fphar.2022.874176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Manoharan-basil SS, González N, Laumen JGE, Kenyon C. Horizontal Gene Transfer of Fluoroquinolone Resistance-Conferring Genes From Commensal Neisseria to Neisseria gonorrhoeae: A Global Phylogenetic Analysis of 20,047 Isolates. Front Microbiol 2022;13:793612. [DOI: 10.3389/fmicb.2022.793612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Basarab GS, Ghorpade S, Gibhard L, Mueller R, Njoroge M, Peton N, Govender P, Massoudi LM, Robertson GT, Lenaerts AJ, Boshoff HI, Joerss D, Parish T, Durand-Reville TF, Perros M, Singh V, Chibale K. Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones. Antimicrob Agents Chemother 2022;:e0219221. [PMID: 35266826 DOI: 10.1128/aac.02192-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Williams E, Fairley CK, Williamson D. Novel strategies for prevention and treatment of antimicrobial resistance in sexually-transmitted infections. Curr Opin Infect Dis 2021;34:591-8. [PMID: 34545855 DOI: 10.1097/QCO.0000000000000793] [Reference Citation Analysis]
10 Newman LM, Kankam M, Nakamura A, Conrad T, Mueller J, O'Donnell J, Osborn BL, Gu K, Saviolakis GA. Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults. Antimicrob Agents Chemother 2021;65:e0129221. [PMID: 34606332 DOI: 10.1128/AAC.01292-21] [Reference Citation Analysis]
11 Xu WQ, Zheng XL, Liu JW, Zhou Q, Zhu XY, Zhang J, Han Y, Chen K, Chen SC, Chen XS, Yin YP. Antimicrobial Susceptibility of Ertapenem in Neisseria gonorrhoeae Isolates Collected Within the China Gonococcal Resistance Surveillance Programme (China-GRSP) 2018. Infect Drug Resist 2021;14:4183-9. [PMID: 34675563 DOI: 10.2147/IDR.S335252] [Reference Citation Analysis]
12 Unemo M, Ahlstrand J, Sánchez-Busó L, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ; European Collaborative Group. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018. J Antimicrob Chemother 2021;76:1221-8. [PMID: 33564854 DOI: 10.1093/jac/dkab024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson TN, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model. Front Pharmacol 2021;12:682135. [PMID: 34093206 DOI: 10.3389/fphar.2021.682135] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Terreni M, Taccani M, Pregnolato M. New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules 2021;26:2671. [PMID: 34063264 DOI: 10.3390/molecules26092671] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Ropponen HK, Richter R, Hirsch AKH, Lehr CM. Mastering the Gram-negative bacterial barrier - Chemical approaches to increase bacterial bioavailability of antibiotics. Adv Drug Deliv Rev 2021;172:339-60. [PMID: 33705882 DOI: 10.1016/j.addr.2021.02.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
16 Smolarczyk K, Mlynarczyk-Bonikowska B, Rudnicka E, Szukiewicz D, Meczekalski B, Smolarczyk R, Pieta W. The Impact of Selected Bacterial Sexually Transmitted Diseases on Pregnancy and Female Fertility. Int J Mol Sci 2021;22:2170. [PMID: 33671616 DOI: 10.3390/ijms22042170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kong Q, Yang Y. Recent advances in antibacterial agents. Bioorg Med Chem Lett 2021;35:127799. [PMID: 33476772 DOI: 10.1016/j.bmcl.2021.127799] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
18 Ferreyra C, Osborn J, Moussy F, Alirol E, Lahra M, Whiley D, Shafer W, Unemo M, Klausner J, Kelly Cirino C, Wi T. Developing target product profiles for Neisseria gonorrhoeae diagnostics in the context of antimicrobial resistance: An expert consensus. PLoS One 2020;15:e0237424. [PMID: 32870912 DOI: 10.1371/journal.pone.0237424] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]